- CA$17.62m
- CA$15.02m
- CA$9.63m
- 71
- 56
- 39
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.23% | ||
| Return on Equity | -21.42% | ||
| Operating Margin | -94.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 12.88 | 15.12 | 17.2 | 18.84 | 9.63 | n/a | n/a | -3.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +79.97 | +30.83 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
Directors
- Glenn Rourke NEC
- Gilles Gagnon CEO
- Stacy Prefontaine CFO
- Ulrich Kosciessa IND
- William Li IND (58)
- Donald Oborowsky IND
- John Zupancic IND
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 1st, 2016
- Public Since
- November 18th, 1987
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 78,293,177
- Address
- 7824 51 Ave NW, EDMONTON, T6E 6W2
- Web
- https://www.ceapro.com/
- Phone
- +1 7804214555
- Contact
- Jenene Thomas
- Auditors
- Grant Thornton LLP
Upcoming Events for CZO
Q2 2024 Ceapro Inc Earnings Release
Q3 2024 Ceapro Inc Earnings Release
Similar to CZO
Arch Biopartners
TSX Venture Exchange
biOasis Technologies
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
FAQ
What is the Ceapro share price?
As of Today at 19:52 UTC, shares in Ceapro are trading at CA$0.23. This share price information is delayed by 15 minutes.
How has the Ceapro share price performed this year?
Shares in Ceapro last closed at CA$0.23 and the price had moved by -51.09% over the past 365 days. In terms of relative price strength the Ceapro share price has underperformed the Toronto Stock Exchange 300 Composite Index by -56.02% over the past year.
What are the analyst and broker recommendations for Ceapro?
The overall consensus recommendation for Ceapro is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ceapro dividend yield?
Ceapro does not currently pay a dividend.
Does Ceapro pay a dividend?
Ceapro does not currently pay a dividend.
When does Ceapro next pay dividends?
Ceapro does not currently pay a dividend.
How do I buy Ceapro shares?
To buy shares in Ceapro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ceapro?
As of the previous close price of CA$0.23, shares in Ceapro had a market capitalisation of CA$17.62m.
Where are Ceapro shares listed?
Here are the trading details for Ceapro:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: CZO
What kind of share is Ceapro?
Based on an overall assessment of its quality, value and momentum Ceapro is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ceapro share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Ceapro share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ceapro. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -17.51%.
As of the last closing price of CA$0.23, shares in Ceapro were trading -20.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ceapro PE Ratio?
The Ceapro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ceapro?
Ceapro's management team is headed by:
- Glenn Rourke - NEC
- Gilles Gagnon - CEO
- Stacy Prefontaine - CFO
- Ulrich Kosciessa - IND
- William Li - IND
- Donald Oborowsky - IND
- John Zupancic - IND